Isotretinoin therapy for progressive systemic sclerosis

Bahmer, F. A.

doi:10.1001/archderm.121.3.308b

Cited by 9 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usefulness of retinoids (retinoic acid) in treating skin sclerosis of systemic scleroderma has been reported in the literature [ 1 , 2 , 7 ]. Retinoids decrease collagen synthesis [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Patient with Localized Scleroderma Successfully Treated with Etretinate

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…There are several treatment methods for localized scleroderma, but treatment is difficult when the lesion is widely distributed. Systemic scleroderma cases in whom vitamin A derivatives are effective for skin sclerotic lesions are reported in the literature [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

A Patient with Localized Scleroderma Successfully Treated with Etretinate

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Systemic or topical retinoids have been reported to be a successful treatment for skin sclerosis due to systemic sclerosis. 10,11 It was suggested that oral etretinate treatment may be a plausible new therapy for sclerodermatous chronic graft-versus-host disease. 12 Our results were thought to support this trend.…”

Section: Discussionmentioning

confidence: 99%

The effects of vitamin A derivative etretinate on the skin of MRL mice

Ikeda

Nishide

Ohtani

et al. 2005

Lupus

View full text Add to dashboard Cite

MRL/Mp-lpr/lpr (MRL/lpr) mice are characterized by the disorder of apoptosis due to defects in Fas antigens and autoimmune symptoms including spontaneous lupus erythematosus (LE)-like skin lesions. MRL/Mp- + / + (MRL/n) mice do not carry the defect of lpr mutation nor do they exhibit skin disorders during the first six months of life. Retinoids are known to inhibit the proliferation of skin fibroblasts, collagen synthesis, modulate immune responses, and apoptosis by Fas ligand upregulation in skin fibroblasts. We examined changes in dermal thickness and appearance of skin disorders in five months old MRL/lpr mice by oral treatment with etretinate, a retinoic acid derivative. Etretinate treated MRL/lpr mice did not have skin lesions or dermatopathological characteristics including an increase in cells infiltrating the dermis. The mean dermal thickness of MRL/lpr and MRL/n mice treated with etretinate decreased significantly and apoptotic cells density in the dermis of MRL/lpr mice with etretinate was significantly higher compared with the control group (P < 0.05) although MRL/lpr mice have a defect within the Fas antigen. We assumed that etretinate reduced dermal thickness, and suppressed the appearance of skin lesions by inducting apoptosis and perhaps regulation of cytokine expression.

show abstract

“…have been reported to be successful for the treatment of the skin sclerosis due to SSc [3,4]. Malcellus et al suggested that treatment with etretinate orally for scierodermatous chronic graft-versus-host disease may present a new therapeutic option [5].…”

Section: The Vitamin a Derivative Etretinate Improves Skin Sclerosis mentioning

confidence: 99%